GCM
NVO

Genus Capital Management’s Novo Nordisk NVO Stock Holding History

Genus Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,559
Closed -$2.33M – 328
2024
Q1 		$2.25M Buy
+17,559
New +$2.09M 0.29% 106
2023
Q4 		– Sell
-17,352
Closed -$1.72M – 322
2023
Q3 		$1.58M Buy
17,352
+1,272
+8% +$112K 0.25% 108
2023
Q2 		$1.3M Buy
+16,080
New +$1.31M 0.19% 122

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Genus Capital Management's NVO Position: Q2 2024 in Review

Genus Capital Management sold out of Novo Nordisk (NVO) in Q2 2024, closing a stake of 17,559 shares — an estimated $2.33M sold.

Genus Capital Management first reported a position in NVO in Q2 2023 and held it in 3 quarters. The position peaked at $2.25M in Q1 2024. 1,860 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

  • Genus Capital Management reported no remaining Novo Nordisk position as of Q2 2024 after selling out during the quarter.
  • Genus Capital Management sold 17,559 Novo Nordisk shares in Q2 2024, an estimated $2.33M.
  • Genus Capital Management first reported a position in Novo Nordisk in Q2 2023 and held it in 3 quarters.
  • Genus Capital Management's Novo Nordisk position peaked at $2.25M in Q1 2024.
  • 1,860 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Genus Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.